SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc – ‘10-K’ for 12/31/04 – EX-10.12

On:  Tuesday, 7/19/05, at 5:26pm ET   ·   For:  12/31/04   ·   Accession #:  1193125-5-144652   ·   File #:  0-19627

Previous ‘10-K’:  ‘10-K’ on 3/3/04 for 12/31/03   ·   Next:  ‘10-K’ on 3/16/06 for 12/31/05   ·   Latest:  ‘10-K’ on 3/21/24 for 12/31/23   ·   26 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 7/19/05  Biolase, Inc                      10-K       12/31/04   17:2.2M                                   RR Donnelley/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Form 10-K for Biolase Technology, Inc.              HTML   1.41M 
 2: EX-10.12    Amendment to Credit Agreement                       HTML     24K 
 3: EX-10.14    Amendment No. 1 to Asset Purchase Agreement Dated   HTML     18K 
                          May 16, 2003                                           
 4: EX-10.15    Amendment No. 2 to Asset Purchase Agreement Dated   HTML     16K 
                          May 20, 2003                                           
 5: EX-10.19    Employment Agreement Dated October 24, 2004         HTML     85K 
 6: EX-10.20    Employment Agreement Dated October 26, 2004         HTML     74K 
 7: EX-10.22    Form of Stock Option Agreement                      HTML     39K 
 8: EX-10.25    Amended and Restated 2002 Option Plan               HTML     96K 
 9: EX-10.26    Form of Stock Option Agreement Under the 2002       HTML     54K 
                          Stock Option Plan                                      
10: EX-10.27    Standard Industrial/Commercial Single-Tenant Lease  HTML    218K 
11: EX-10.28    Basic Sublease Terms                                HTML     29K 
12: EX-21.1     Subsidiaries of the Registrant                      HTML      7K 
13: EX-23.1     Consent of Independent Registered Public            HTML      9K 
                          Accounting Firm                                        
14: EX-31.1     Certification of Robert E. Grant Pursuant to Rule   HTML     15K 
                          13A-14(A) and Rule 15D-14(A)                           
15: EX-31.2     Certification of John Hohener Pursuant to Rule      HTML     15K 
                          13A-14(A) and Rule 15D-14(A)                           
16: EX-32.1     Certification of Robert E. Grant Pursuant to        HTML     10K 
                          Section 906                                            
17: EX-32.2     Certification of John Hohener Pursuant to Section   HTML     10K 
                          906                                                    


EX-10.12   —   Amendment to Credit Agreement


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Amendment to Credit Agreement  

EXHIBIT 10.12

 

CHANGE IN TERMS AGREEMENT

 

Principal

   Loan Date

   Maturity

   Loan No

   Call / Coll

   Account

   Officer

  Initials

$10,000,000.00    05-14-2003    06-30-2005    0054468275              ***    

 

References in the shaded area are for Lender’s use only and do not limit the applicability of this document to any particular loan or item.

 

Any item above containing “***” has been omitted due to text length limitations.

 

Borrower:   

BIOLASE TECHNOLOGY, INC.

981 Calle Amancer

San Clemente, CA 92673

   Lender:   

BANK OF THE WEST

Newport Beach BBC #163

4400 MacArthur Boulevard

Newport Beach, CA 92660

(888) 457-2692

 

Principal Amount: $10,000,000.00   Date of Agreement: June 1, 2004

 

DESCRIPTION OF EXISTING INDEBTEDNESS.

 

Credit Agreement (LINE OF CREDIT) dated May 14, 2003 in the original principal amount of $4,500,000.00.

 

DESCRIPTION OF COLLATERAL.

 

UCC-1 blanket lien on all equipment, inventory, accounts, documents, monies and assets.

 

DESCRIPTION OF CHANGE IN TERMS.

 

1. Modification of Credit Percentage. The Credit Percentage provided for in Section 1.1.7 of the Credit Agreement shall be changed to 10%.

 

2. Extension of Expiration Date. The Expiration Date provided for in Section 1.1.17 of the Credit Agreement shall be extended to June 30, 2005.

 

3. Change in Line of Credit Dollar Amount. The dollar amount for Line of Credit provided for in Section 2.1.1 of the Credit Agreement shall be changed to $10,000,000.00.

 

4. Modification of Reporting and Certification Requirements. Section 6.1 (i) of the Credit Agreement is deleted in its entirety and the following is substituted in lieu thereof:

 

6.1. (i) Not later than 105 days after the end of each of the Borrower’s fiscal years, a copy of the annual financial report of the Borrower for such year audited by a firm of certified public accountants acceptable to the Lender.

 

5. Deleting Reporting and Certification Requirements. Section 6.1 (iii) of the Credit Agreement is deleted in its entirety.

 

6. Modification of Financial Condition. Section 6.2 of the Credit Agreement is deleted in its entirety and the following is substituted in lieu thereof:

 

6.2 Financial Condition: The Borrower promises and agrees, during the term of this Agreement and until payment in full of all of the Borrower’s Obligations, the Borrower will maintain at all times:

 

(i) A minimum Effective Tangible Net Worth of at least $30,000,000.00.

 

(ii) A ratio of Debt to Effective Tangible Net Worth of not more than 1.000 to 1.000.

 

(iii) Cash, cash equivalents and marketable securities of not less than $20,000,000.00.

 

(iv) Profitability by not allowing any quarterly losses.

 

(v) A ratio of Funded Debt to EBITDA of not more than 1.25 to 1 at the end of each fiscal quarter, with EBITDA based upon the immediately preceding three fiscal quarters and the current quarter just ended.

 

7. Deleting Payment of Dividends, Redemption or Repurchase of Stock, Additional indebtedness, Loans, Liens and Encumbrances and Capital Expense. Section 6.9, 6.10, 6.11, 6.12, 6.13 and 6.18 of the Credit Agreement are deleted in their entirety.

 

8. Conditions Precedent. As a condition precedent to the effectiveness of this Change In Terms Agreement, Borrower agrees to pay to Lender a fee of $25,000.00.

 

CONTINUING VALIDITY. Except as expressly changed by this Agreement, the terms of the original obligation or obligations, including all agreements evidenced or securing the obligation(s), remain unchanged and in full force and effect. Consent by Lender to this Agreement does not waive Lender’s right to strict performance of the obligation(s) as changed, nor obligate Lender to make any future change in terms. Nothing in this Agreement will constitute a satisfaction of the obligation(s). It is the intention of Lender to retain as liable parties all makers and endorsers of the original obligation(s), including accommodation parties, unless a party is expressly released by Lender in writing. Any maker or endorser, including accommodation makers, will not be released by virtue of this Agreement. If any person who signed the original obligation does not sign this Agreement below, then all persons signing below acknowledge that this Agreement is given conditionally, based on the representation to Lender that the non-signing party consents to the changes and provisions of this Agreement or otherwise will not be released by it. This waiver applies not only to any initial extension, modification or release, but also to all such subsequent actions.

 

CONTINUED ON NEXT PAGE

 


CHANGE IN TERMS AGREEMENT

(Continued)

 

Loan No: 0054468275    

 

PRIOR TO SIGNING THIS AGREEMENT, BORROWER READ AND UNDERSTOOD ALL THE PROVISIONS OF THIS AGREEMENT. BORROWER AGREES TO THE TERMS OF THE AGREEMENT.

 

CIT SIGNERS:

       

BIOLASE TECHNOLOGY, INC.

       
By:   /s/    JEFFREY W. JONES               By:   /s/    EDSON J. ROOD        
    Jeffrey W. Jones,
President of BIOLASE TECHNOLOGY, INC.
          Edson J. Rood,
Chief Financial Officer of BIOLASE TECHNOLOGY, INC.

 

BANK OF THE WEST
By:   /s/    JAMES E. MARTIN        
    James E. Martin,
Vice President of BANK OF THE WEST

 

Page 2


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:7/19/0510-Q/A,  8-K
6/30/0510-Q,  NTN 10Q
For Period End:12/31/04NT 10-K
6/1/04
5/14/03
 List all Filings 


26 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/19/24  Biolase, Inc.                     POS AM                 1:1.1M                                   Donnelley … Solutions/FA
 4/11/24  Biolase, Inc.                     POS AM                 3:1.1M                                   Donnelley … Solutions/FA
 3/27/24  Biolase, Inc.                     S-1/A                  5:1.1M                                   Donnelley … Solutions/FA
 3/21/24  Biolase, Inc.                     10-K       12/31/23   99:18M                                    Donnelley … Solutions/FA
 2/09/24  Biolase, Inc.                     S-1/A                  4:3M                                     Donnelley … Solutions/FA
 2/07/24  Biolase, Inc.                     S-1/A                  8:3.3M                                   Donnelley … Solutions/FA
 1/31/24  Biolase, Inc.                     S-1/A                  9:3.2M                                   Donnelley … Solutions/FA
 1/19/24  Biolase, Inc.                     S-1                    3:2.6M                                   Donnelley … Solutions/FA
12/26/23  Biolase, Inc.                     S-1                    4:496K                                   Donnelley … Solutions/FA
 9/11/23  Biolase, Inc.                     S-1/A                  4:868K                                   Donnelley … Solutions/FA
 9/05/23  Biolase, Inc.                     S-1/A       9/01/23    2:830K                                   Donnelley … Solutions/FA
 8/30/23  Biolase, Inc.                     S-1/A                  8:1.3M                                   Donnelley … Solutions/FA
 8/18/23  Biolase, Inc.                     S-1/A                  2:720K                                   Donnelley … Solutions/FA
 8/14/23  Biolase, Inc.                     S-1/A       8/11/23    8:1.3M                                   Donnelley … Solutions/FA
 7/21/23  Biolase, Inc.                     S-1                    3:800K                                   Donnelley … Solutions/FA
 5/24/23  Biolase, Inc.                     S-1/A                  7:1.2M                                   Donnelley … Solutions/FA
 5/22/23  Biolase, Inc.                     S-1/A                  8:1.3M                                   Donnelley … Solutions/FA
 5/18/23  Biolase, Inc.                     S-1/A                  8:1.2M                                   Donnelley … Solutions/FA
 5/04/23  Biolase, Inc.                     S-1                    3:750K                                   Donnelley … Solutions/FA
 3/28/23  Biolase, Inc.                     10-K       12/31/22   90:19M                                    Donnelley … Solutions/FA
 1/03/23  Biolase, Inc.                     S-1/A                  6:1M                                     Donnelley … Solutions/FA
12/12/22  Biolase, Inc.                     S-1/A                  7:1.1M                                   Donnelley … Solutions/FA
11/22/22  Biolase, Inc.                     S-1                    3:655K                                   Donnelley … Solutions/FA
 3/17/22  Biolase, Inc.                     10-K       12/31/21   88:18M                                    Donnelley … Solutions/FA
 3/31/21  Biolase, Inc.                     10-K       12/31/20   88:15M                                    ActiveDisclosure/FA
12/08/20  Biolase, Inc.                     S-1/A                  3:585K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001193125-05-144652   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 3, 1:56:32.2am ET